Reactions mediated by the opiate receptors that inhibit adenylate cyclase (EC 4.6.1.1) are closely coupled to subsequent reactions that gradually increase adenylate cyclase activity of neuroblastoma X gboma NGl68-15 hybrid cells. Opiate-treated cells have higher basal-, prostaglandin El-, and 2chloroadenosine-stimulated activities than do control cells. However, NaF or guanosine S'#,y-imidobiphosphate abolishes most of the difference in adenylate cyclase activity observed with homogenates from control and opiate-treated cells. Cyclobeximide blocked some, but not all, of the opiatedependent increase in adenylate cyclase activity. These results suggest t&t the opiatedependent increase in adenylate cyclase is due to conversion of adenylate cyclase to a form with altered activity. Protein synthesis also is re uired for part of the opiate effect. We propose that activity o s adenylate cyclase determines the rate of conversion of the enzym'e from one form to the other and that o iates b inhibiting adenylate cyclase, alter the relative abun dP 'Y ante of ow-and high-activity forms of the enzyme.
of adenylate cyclase [ATP pyropbospbate-lyase (cyclizing) , EC 4.6.1.11 by opiates is rapidly reversed upon removal of opiate (l-3). However, exposure of ceils to an opiate for 12 or more hours results in a compensatory increase in adenylate cyclase activity that is long-lived and not readily reversed by withdrawal of the opiate (4-6). Similar dual regulations of adenylate cyclase activity are mediated by cu-adrenergic receptors (7) and excitatory muscarinic acetylcholine receptors (S. K. Sharma and M. Nirenberg, unpublished data; ref. 8) . Thus, dual regulation may he a general regulatory mechanism which alters the responsiveness of adenylate cyclase to activations mediated by other species of receptors. Because the mechanism of coupling i+ibition of adenylate cyclase with a subsequent increase in enzyme activity is unknown, we examined the properties of adenylate cyclase from control cells and cells treated with opiates.
MATERIALS AND METHODS
The source of each chemical, growth conditions for culturing neuroblastoma x glioma NG108-15 hybrid cells, and preparation of homogenates have heen described (2). Adenylate cyclase activity was measured by the procedure of Salomon et al. (9) , modified slightly (2). Each tube contained 30 mM Tris-HCl, pH 7.5/5 mM MgC&/160 mM sucrose/20 mM creatine phosphate/10 units of creatine kinase (65 pg of protein)/1 mM adenosine 3':5'-cyclic monophosphate (cAMP)/0.5 mM 4-(3-butoxy-4-metboxybenzy!)-2-imidazolidinone (Ro 20-1724)/ 0.5% ethanol/l mM (cu-~P]ATP (3 to 5 X l@ cpm) and 50-200 pg of homogenate protein in a final volume of 100 ~1. Incubations were for 5 min at 37".
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Effect of Activators of Adenylate Cyclase. If the increase in adenylate cyclase activity of opiate-treated NG108-15 cells were due primarily to an increase in the number of molecules of adenylate cyclase, the relatively high enzyme activity of opiate-treated cells should he maintained under other assay conditions. For this reason, we studied the effects of activators and inhibitors on adenylate cyclase of cells grown in the presence or absence of morphine or etorphine for 3-5 days. Sodium fluoride is known to activate hasal adenylate cyclase and inhibit activation of the enzyme by hormones, presumably by uncoupling the enzyme from the hormone-receptor complex (10). The effects of NaF upon basal and prostaglandin El (PGEl)-stimulated adenylate cyclase activity from control or etorpbine-treated NG108-15 cells as a function of time are shown in Fig. 1 . In the presence of 8 mM NaF, the basal activities of adenylate cyclase from control and opiate-treated cells were increased 4.3-and 2.6-fold, respectively, and the specific activities of the two enzyme preparations then were similar. Conversely, the activities of PGE&imu~ted adenylate cyclase from control and opiate-treated cells were inhibited 44% and 60%, respectively, by NaF and the final specific activities were similar. These results show that adenylate cyclase from control cells is more responsive to activation by NaF than adenylate cyclase of opiate-treated cells and raise the possibility that the relatively high activity of adenylate cyclase of opiate-treated cells may be due to enzyme activation rather than to an increase in the number of enzyme molecules.
In other systems, guanosine 5'.(P,y-imido)triphospbate
[GP~NWPI has bee n s h own to activate hasal adenylate cyclase and to activate or inhibit adenylate cyclase synergistically with hormones initially but ultimately to uncouple adinylate cyclase from the hormone-receptor complex (11, 12 The effects of different concentrations of NaF or Gpp(NH)p on the activities of adetiylate cyclase from control or opiatetreated NG108-15 cells are shown in Fig. 3 . At relatively low concentrations of activator [Z mM NaF or 5 PM Gpp(NH)p], basal adenylate cyclase of control cells was activated but not the enzyme of opiate-treated cells. Higher concentrations of NaF or Gpp(NH)p increased the enzyme activity from both control and opiate-treated cells to the same extent, but the specific activities of the two enzyme preparations were almost the same. Conversely, PGEl-stimulated adenylate cyclase of control cells was inhibited less by NaF or Gpp(NH)p than the enzyme from opiate-treated cells. Both the PGEl-stimulated and basal activities of adenylate cyclase from control cells almost equaled those of opiate-treated cells in the presence of 2 mM NaF or 5 FM Gpp(NH)p. The concentrations of Gpp(NH)p or NaF required for half-maximal inhibition of PGEI-stimulated adenylate cyclase were similar to the concentrations required for half-maximal reversal of the difference between control and opiate-treated adenylate cyclase activity (3 PM Gpp(NH)p or 1.5 mM NaF). Higher concentrations of Gpp(NH)p (50 PM) or NaF (4 mM) were required for halfmaximal activation of basal adenylate cyclase. Thus, reversal of the difference between control and opiate-treated adenylate cyclase activities resembles the uncoupling of a receptor from adenylate cyclase.
The hybrid cells were incubated with or without cycloheximide in the presence or absence of etorphine to determine whether inhibition of protein synthesis affected the opiatedependent increase in adenylate cyclase activity (Fig. 4) . Cycloheximide blocked the etorphine-dependent increase in adenylate cyclase at 10 and 20 hr of incubation but not at 4 hr. Similar results were obtained in other experiments not shown here. Although the toxic effects of cycloheximide on cells limited the duration of cell incubation and decreased the magnitude of the etorphine-dependent increase in adenylate cyclase activity, the results show that adenylate cyclase is a relatively stable enzyme that does not turn over rapidly under the conditions tested and suggest that most, but not all, of the increase in adenylate cyclase activity evoked by etorphine is dependent on protein synthesis. The results should be interpreted with caution because cycloheximide probably affects many reactions, directly or indirectly, during the long incubation period.
The effects of varying PGEl or 2-chloroadenosine (13, 14)
Biochemistry: Sharma et al. In each 30-mm diameter dish, 770,ooO cells were plated in 2 ml of 90% Dulbecco-Vogt modification of Eagle's medium supplemented with 1096 fetal bovine serum, 100 NM hypoxanthine, 1 PM aminopterin, and 12 FM thymidine. Cycloheximide blocked incorporation of ]3H]proline into protein almost completely. After 20 hr under these conditions, cells tended to detach from the dish. Cell protein was harvested quantitatively after 4,10, or 20 hr of incubation at 37" in 10% CO2/90?6 air. Cells were removed and recovered by centrifugation at 400 X g for 5 min and washed three times with buffered saline adjusted to 340 mosmol/liter, pH 7.4. Each washed pellet was suspended in 1 ml of 320 mM sucrose/l0 mM Tri*HCl, pH 7.5, and stored at -80° prior to assay for adenylate cyclase activity and for protein. concentrations of adenylate cyclase activity from control and etorphine-treated cells are shown in Fig. 5 . Half-maximal activations of adenylate cyclase from control and opiate-treated cells were obtained with approximately 0.15 PM PGEl or 1.8 FM 2-chloroadenosine. Concentrations of 2-chloroadenosine >50 FM were inhibitory. The results show that the increase in adenylate cyclase activity due to treatment of cells with opiates and stimulation of adenylate cyclase by PGEl or 2-chloroadenosine are expressed simultaneously and that treatment of cells with opiates does not alter the concentrations of PGEl or 2-chloroadenosine required for half-maximal activation of adenylate cyclase by PGEl or 2-chloroadenosine. Therefore, the supersensitivity of opiate-treated cells to PGEl or 2-chloroadenosine results from an increase in adenylate cyclase activity.
Interaction between Receptors Coupled to the Inhibition or Activation of Adenylate Cyclase. The relationship between morphine concentration and inhibition of adenylate cyclase from control and opiate-treated cells is shown in Fig. 6 A and B, and the effects of different concentrations of naloxone in reversing the inhibition of adenylate cyclase by 10 PM morphine are shown in Fig. 6 C and D. Half-maximal inhibition of basal adenylate cyclase from control and morphine-treated cells was obtained with 1 PM morphine and maximal inhibition with S-10 PM morphine (Fig. 6B) . However, in the presence of PGE1, a lO-to 2@fold higher concentration of morphine (100 PM or more) was required for maximal inhibition of adenylate cyclase from control or opiate-treated cells (Fig. 6A) . Conversely, a IO-fold lower concentration of naloxone (5 FM) was required for complete reversal of inhibition of adenylate cyclase by morphine in the presence of PGEl than in the absence of PGEl (50 PM naloxone). These results show that inhibitory opiate receptors and stimulatory PGEl receptors interact at the level of adenylate cyclase. Similarly, PGE1 increased the effectiveness of naloxone in reversing the inhibition of adenylate cyclase by morphine. Perhaps both phenomena are a conse- quence of the loss of positive cooperativity in the coupling of the morphine-opiate receptor complex with adenylate cyclase (Hill coefficient = 2). Naloxone and PGEl would be expected to act by different mechanisms because naloxone and morphine compete for a site on the opiate receptor, whereas the morphineepiate receptor and the PGEl.PGEl receptor either might compete for sites coupling receptors to adenylate cyclase, or both species of receptor might be coupled simultaneously to adenylate cyclase at separate sites and interact by an allosteric mechanism. The data also show that the long-lived activation of adenylate cyclase that results from prolonged exposure of NG108-15 cells to an opiate and the transient inhibition of adenylate cyclase by morphine are expressed independently and simultaneously. Tolerance and dependence produced in animals by chronic exposure to opiates can be understood at the cellular level in terms of an increase in adenylate cyclase activity (4-6). Opiate-treated cells are tolerant to opiates because the relatively high adenylate cyclase activity of such cells must be inhibited to a greater extent by the opiate before levels of enzyme activity and of CAMP fall below the levels of control cells. They are dependent upon opiates because withdrawal of the opiate reverses the inhibition of adenylate cyclase and thereby increases the CAMP level well above that of control cells. Finally, opiate-treated cells are supersensitive to the opiate antagonist naloxone because opiate-treated cells have more adenylate cyclase activity and more opiate-inhibited enzyme activity than control cells. Consequently, at any concentration of naloxone, more adenylate cyclase activity is rescued with homogenates from opiate-treated cells than with those from control cells when both are assayed in the presence of morphine..
In experiments not shown here, the pH optimum of adenylate cyclase from control or morphine-treated cells was pH 8.5 for basal activity and pH 8.0 for PGEl-stimulated activity, The apparent Michaelis constant (K,) for ATP was 0.16 mM with adenylate cyclase from control cells and opiate-treated cells with or without PGE,. The numbers shown are pM and are K, values for ATP, K. values for PGEl and 2-chloroadenosine, or concentrations required for half-maximal stimulation or inhibition of adenylate cyclase by MgC12, Gpp(NH)p, NaF, morphine, or naloxone (the last in the presence of 10 pM morphine). The PGEl concentration was 10 rM except where indicated.
The effects of Mg2+ and Mn 2+ concentrations on basal and PGEl-stimulated adenylate cyclase activities from control on morphine-treated cells are shown in Fig. 7 . The concentrations of Mg2+ required for maximal, activation of basal and PGElstimulated adenylate cyclase were approximately 30 and 2 mM, respectively, with both enzyme preparations. Thus, Mg2+ and PGEl activate adenylate cyclase synergistically. Higher concentrations of Mg2+ inhibited adenylate cyclase, and the enzyme from morphine-treated cells was more sensitive to inhibition than that from control cells. The concentrations of Mn*+ required for maximal stimulation of basal and PGEl-stimulated adenylate cyclase were 2 and 1 mM, respectively. Higher concentrations of Mn2+ were inhibitory.
In Table 1 , K, values for ATP, K, values for PGEl or 2-chloroadenosine, or concentrations of Mg2', Mn2+, Gpp(NH)p, or NaF required for 50% of the maximal effect are summarized and are shown to be the same for adenylate cyclase from control and opiate-treated cells. Similarly, no difference was found in the concentration of morphine required for half-maximal inhibition of adenylate cyclase or in the concentration of naloxone required for reversal of morphine inhibition of adenylate cyclase.
DISCUSSION
Opiates regulate adenylate cyclase in two ways, both mediated by the opiate receptor. Opiates inhibit adenylate cyclase rapidly and reversibly, and the inhibition is coupled to a gradual, long-lived increase in adenylate cyclase activity that is expressed even in the absence of the opiate. In this report, the properties of adenylate cyclase from neuroblastoma X glioma hybrid cells cultured with or without opiates for several days are compared. Adenylate cyclase preparations from control and opiate-treated cells do not differ appreciably with respect to the concentrations of PGEl, 2-chloroadenosine, morphine, naloxone, ATP, Mg2+, or Mn2+ required for half-maximal effects. However, Gpp(NH)p or NaF abolishes most, but not all, of the opiate-dependent increase in adenylate cyclase activity. Basal adenylate cyclase of opiate-treated cells is activated less by Gpp(NH)p or NaF, and the PGEl-stimulated enzyme is inhibited more by these compounds, than the enzyme from control cells.
Because the mechanisms of activation and inhibition of adenylate cyclase by Gpp(NH)p or NaF are not understood and
